- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial completion date, Trial primary completion date, Metastases: A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 2, 2024 P3, N=401, Recruiting, Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date: Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC (clinicaltrials.gov) - Apr 2, 2024 P2, N=70, Recruiting, Furthermore, the developed GBM-on-a-chip model provides a potential ex vivo platform for innovative cell-based therapies and tailored therapeutic strategies for GBM. Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Jan 2024
- |||||||||| Lipusu (liposomal paclitaxel) / Luye Group
Journal, Metastases: Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy. (Pubmed Central) - Mar 29, 2024 The precise molecular switch also helped to increase the PTX maximum tolerated dose from 25 In in vivo study, PTX-Rh2-lipo effectively inhibiting the growth of advanced breast tumors and outperformed most reported PTX formulations, including Lipusu
- |||||||||| APG-1387 / Ascentage Pharma
Trial completion date, Trial primary completion date, Metastases: APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 29, 2024 P1/2, N=44, Recruiting, In in vivo study, PTX-Rh2-lipo effectively inhibiting the growth of advanced breast tumors and outperformed most reported PTX formulations, including Lipusu Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- |||||||||| Journal: IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone. (Pubmed Central) - Mar 25, 2024
The regimen, called IPIAD, uses an angiotensin receptor blocker (ARB) irbesartan indicated for treating hypertension, an old antimicrobial drug pyrimethamine indicated for treating toxoplasmosis or malaria, an old antifungal drug itraconazole, an old broad spectrum antibiotic azithromycin and an old antibiotic dapsone. In reviewing selected growth driving systems active in pancreatic ductal adenocarcinoma then comparing these with detailed data on ancillary attributes of the IPIAD drugs, one can predict clinical benefit and slowing growth of pancreatic ductal adenocarcinoma by this augmentation regimen.
- |||||||||| albumin-bound paclitaxel / Generic mfg.
Journal, Metastases: Regimen Selection by Narrative Approach in Patients with Advanced Gastric Cancer-Paclitaxel or Nab-Paclitaxel? (Pubmed Central) - Mar 22, 2024 Here, we report a case of metachronous oligo-hepatic and peritoneal metastases in a patient who survived without recurrence for 3 Questionnaire survey suggests that we may select the patients for nab-PTX properly by clarifying the inconvenience of daily life associated with premedication, the way of transportation for visiting hospital, and the benefits by shortening of infusion time.
- |||||||||| albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Metastases: PTCA199-9: Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Mar 21, 2024 P2, N=30, Recruiting, Questionnaire survey suggests that we may select the patients for nab-PTX properly by clarifying the inconvenience of daily life associated with premedication, the way of transportation for visiting hospital, and the benefits by shortening of infusion time. Not yet recruiting --> Recruiting
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
TROPION-Breast05: Phase (Ph) 3 study of datopotamab deruxtecan (Dato-DXd) _ durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_510; P3 Secondary endpoints: overall survival, objective response rate, duration of response, investigator-assessed PFS, PFS2, clinical benefit rate at 24 weeks, patient-reported outcomes, pharmacokinetics, immunogenicity, safety. Enrolment is planned in 20 countries/regions; recruitment is active in the UK, South Korea and Taiwan at the time of abstract submission.
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Three-year invasive disease-free survival results from a phase 2 study of pyrotinib plus trastuzumab and albumin-bound paclitaxel as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer (Exhibition area) - Mar 19, 2024 - Abstract #ESMOBC2024ESMO_BC_372; P1/2 After surgery, patients were scheduled to be given 4 cycles of adjuvant anthracycline plus cyclophosphamide, followed by HER2-targeted therapy at the physician's discretion, adjuvant irradiation, and endocrine therapy, if applicable... Compared to the dual-HER2 blockades, adding pyrotinib to the combo regimen of chemotherapy and trastuzumab further improved the pCR rate which consequently translates to the iDFS benefit in non-metastatic BC, justifying the rationality of synergizing small molecule tyrosine kinase inhibitors, trastuzumab, and chemotherapy.
- |||||||||| metformin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Surgery: Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (clinicaltrials.gov) - Mar 18, 2024 P1, N=21, Active, not recruiting, Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Jan 2023 --> Jan 2024 Trial completion date: Dec 2023 --> Dec 2024
- |||||||||| Review, Journal, Metastases: Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Mar 18, 2024
For mPDAC, FOLFIRINOX or gemcitabine plus nab-paclitaxel are the current first-line treatments...Current understanding of the molecular signature and immune landscape of PDAC has motivated the emergence of different targeted and immune-based therapeutic approaches, some of which have shown promising results. The purpose of this review is to discuss the new targets and new drugs for mPDAC in terms of specific pathogenic factors such as metabolic vulnerability, DNA damage repair system, tumor microenvironment and immune system, in order to identify potential vulnerabilities in mPDAC patients and hopefully improve the prognosis of mPDAC patients.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study. (Pubmed Central) - Mar 18, 2024 P1/2 The purpose of this review is to discuss the new targets and new drugs for mPDAC in terms of specific pathogenic factors such as metabolic vulnerability, DNA damage repair system, tumor microenvironment and immune system, in order to identify potential vulnerabilities in mPDAC patients and hopefully improve the prognosis of mPDAC patients. Second-line PD-1 inhibitor combined with albumin paclitaxel and apatinib showed certain efficacy and safety in patients with mGC.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Trial completion date, Combination therapy, Metastases: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Mar 17, 2024 P1, N=76, Active, not recruiting, Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Mar 2024 Trial completion date: Dec 2025 --> Jun 2024
- |||||||||| Trial completion, Enrollment change, Trial completion date, Metastases: Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Mar 15, 2024
P2, N=104, Completed, This study meets the primary endpoint showing potential efficacy of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin, with an acceptable safety profile, in patients with resectable locally advanced HNSCC. Active, not recruiting --> Completed | N=71 --> 104 | Trial completion date: Dec 2024 --> Dec 2023
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Mar 15, 2024 P2, N=63, Active, not recruiting, Active, not recruiting --> Completed | N=71 --> 104 | Trial completion date: Dec 2024 --> Dec 2023 Trial completion date: Dec 2023 --> Dec 2024
- |||||||||| UCT-01-097 / 1200 Pharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: UCT01097-001: First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 15, 2024 P1, N=32, Terminated, N=106 --> 32 | Trial completion date: Aug 2024 --> Feb 2024 | Recruiting --> Terminated | Trial primary completion date: Sep 2023 --> Feb 2024; Stopped for strategic business reasons. The decision to stop the study was not connected to any safety concerns, or new risk associated with the study product, intervention, or procedures.
- |||||||||| cisplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
EFFICACY OF FULLY COVERED SELF-EXPANDABLE METAL STENTS IN PATIENTS WITH HILAR CHOLANGIOCARCINOMA UNDERGOING TRIPLET CHEMOTHERAPY REGIMEN (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7756; Notably, a statistically significant difference ( p <0.05) in cumulative stent patency was observed between plastic stents and FCSEMS in both groups. Conclusions : When bilateral EBD was performed using 6mm FCSEMS in patients with unresectable hilar CCC receiving GCP chemotherapy, better stent patency was shown in both the locally advanced and metastatic groups compared to that of plastic stent, and this was confirmed as a significant result.
- |||||||||| DELTA RADIOMIC FEATURES PREDICT RESECTION MARGIN STATUS AND OVERALL SURVIVAL IN NEOADJUVANT-TREATED PANCREATIC CANCER PATIENTS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7565;
The model that combined preoperative clinical variables (pre-NAT CA19-9, the change in CA19-9 after NAT (?CA19-9), and DRF outperformed all the other models (clinical feature-based models and other radiomics feature-based models) in predicting OS (UTSW: 0.73; Humanitas: 0.66), DFS (UTSW: 0.75; Humanitas: 0.64), and PRMS (UTSW 0.73; Humanitas: 0.69) in both the discovery and validation cohorts. Conclusions Our externally validated model that incorporates delta radiomic features with preoperative clinical data shows promise as a pre-operative tool in predicting OS and DFS and in estimating the risk of an R0 resection in NAT-treated PDAC patients.
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group
ENDOSCOPIC FULL-THICKNESS RESECTION AFTER CONVERSION THERAPY: ORGAN PRESERVATION STRATEGY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5766; Conclusion This study highlights the promising efficacy of EFTR for locally advanced ESCC following conversion therapy, proposing an esophageal preservation approach for patients who are either unsuitable for or decline surgical intervention. Although the EFTR-based esophageal preservation strategy shows considerable benefits, it necessitates validation through more extensive, prospective clinical trials to establish its efficacy and safety in the advanced ESCC patients.
|